TY - JOUR T1 - Highlights from this issue JF - Thorax JO - Thorax SP - i LP - i DO - 10.1136/thoraxjnl-2018-212239 VL - 73 IS - 8 AU - The Triumvirate Y1 - 2018/08/01 UR - http://thorax.bmj.com/content/73/8/i.abstract N2 - To celebrate England’s historic victory/glorious failure (delete as appropriate), this month’s Airwaves plays homage to some of the great moments of World Cup football.When Ivacaftor was developed many people probably felt like the English when they last won the World Cup in 1966. At last a first in class disease modifying drug that targets the underlying molecular defect to improve the function of CFTR. However, in the ‘extra-time’ of clinical trials, namely the post marketing surveillance, the sustained effects are not always that impressive. However, in this issue of Thorax, Bessonova and colleagues assessed the effects of Ivacftor, in routine practice, using data from UK and US registry data ( see page 731). They found ivacaftor-treated individuals had substantially lower risks of death, transplantation, hospitalisation and pulmonary exacerbation relative to comparators. They think CF’s all over, it is now?In Mexico, 1986, Argentina met England in the quarter-finals in what was to be one of the most inflammatory games of the World Cup. In this issue, Jeong et al describe another highly inflammatory process, the consequence of epithelial exposure … ER -